Clinical trials: Autoimmune Bullous Disease
Bullous Pemphigoid
Pilot Efficacy and Safety Study of Oral DF2156A in Patients With Active Bullous Pemphigoid
The objective of this clinical trial was to evaluate whether DF2156A has a potential in improving the clinical outcome in patients with active blistering bullous pemphigoid (BP) to warrant its further development.
- Trial name
- NCT01571895
- Testing
- DF2156A
- Where
- 4 sites in Germany, Italy
- Volunteers
- 4 people
- Sponsor
- Dompé Farmaceutici S.p.A
Pemphigoid, Bullous
Anti-IL-5 Therapy in Bullous Pemphigoid (BP)
Randomized, placebo-controlled, double-blind study evaluating the effect of anti-IL-5-therapy in patients with bullous pemphigoid.
- Trial name
- NCT01705795
- Testing
- Mepolizumab (a-IL-5 antibody)
- Where
- Switzerland
- Volunteers
- 32 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Bullous Pemphigoid
Topical Steroids Alone or Associated With Methotrexate in Bullous Pemphigoid
This controlled multi-center randomized clinical trial, with direct individual benefit, will compare efficacy and safety of two strategies in non-localized BP care: a combined regimen using initial superpotent topical steroids…
- Trial name
- BP/MTX (NCT02313870)
- Testing
- clobetasol propionate + Methotrexate, clobetasol propionate alone
- Where
- France
- Volunteers
- 322 people
- Sponsor
- University Hospital, Montpellier
Pemphigus Vulgaris, Bullous Dermatoses
Comparative Analysis of the Th17 Cellular Response in Active and Inactive Pemphigus Vulgaris Patients
This study will compare the pattern of Th17 immune response in active and inactive pemphigus subjects. Skin and serum samples will be taken at the moment of enrollment.
- Conditions
- Pemphigus Vulgaris, Bullous Dermatoses, Autoimmune Diseases
- Trial name
- NCT04096222
- Where
- 2 sites in Mexico
- Volunteers
- 42 people
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Bullous Pemphigoid, Pemphigoid
Ixekizumab in the Treatment of Bullous Pemphigoid
Recently, Interleukin (IL)-17 has been identified as a key driver of chronic inflammation in Bullous Pemphigoid (BP). Ixekizumab is a recombinant high-affinity fully human monoclonal antibody that targets IL-17A Immunoglobulin…
- Trial name
- NCT03099538
- Testing
- Ixekizumab
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Mayo Clinic
Bullous Dermatoses, Psoriasis
Intradermal Tozinameran for Patients With Immune-mediated Dermatologic Diseases
This is a randomised controlled trial conducted to prove that the immunological performance of intradermal tozinameran (i.e., Pfizer-BioNTech COVID-19 vaccine) is no worse than the standard intramuscular route in patients with…
- Conditions
- Bullous Dermatoses, Psoriasis, COVID-19 Vaccines
- Trial name
- NCT05406908
- Testing
- tozinameran
- Where
- Thailand
- Volunteers
- 109 people
- Sponsor
- Mahidol University
Pemphigus, Bullous Pemphigoid
Human Leukocyte Antigen Class II (DRB1 and DQB1) Alleles and Haplotypes Frequencies in Patients With Pemphigus Vulgaris Among the Russian Population
Pemphigus is a rare autoimmune life-threatening blistering condition affecting skin and mucous membranes. Pemphigus belongs to a family of polygenic disorders.
- Conditions
- Pemphigus, Bullous Pemphigoid, Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses
- Trial name
- NCT05284929
- Testing
- A single blood sample for HLA typing
- Where
- Russia
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Sechenov University
Bullous Pemphigoid
Comparison of Two Therapeutic Strategies of Dermoval in Treatment of Bullous Pemphigus
to compare efficacity and tolerance of two stratégies of dermoval application in treatment of bullous pemphigus.
- Trial name
- NCT00213421
- Testing
- Dermoval
- Where
- France
- Volunteers
- 330 people
- Sponsor
- University Hospital, Rouen
Bullous Pemphigoid
Leflunomide Associated With Topical Corticosteroids for Bullous Pemphigoid
Bullous pemphigoid (BP) is the most common blistering auto-immune disease of skin with an incidence estimated to 400 new cases per year.
- Trial name
- ARABUL (NCT00802243)
- Testing
- leflunomide
- Where
- 3 sites in France
- Volunteers
- 54 people
- Sponsor
- University Hospital, Limoges
Bullous Pemphigoid
Azathioprine or Mycophenolate Mofetil for Bullous Pemphigoid
To investigate the safety and efficacy of oral methylprednisolone combined with azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid.
- Trial name
- NCT00431119
- Testing
- Azathioprine or Mycophenolate mofetil
- Where
- 11 sites in Germany
- Volunteers
- 70 people
- Sponsor
- University Hospital Muenster
Autoimmune Bullous Dermatosis
Coagulopathy of Immunodermatologic Diseases
This study will examine the coagulation and fibrinolysis profiles of those with autoimmune skin diseases. Blood samples will be collected from participants with active/poorly controlled immune-mediated skin diseases and…
- Trial name
- NCT06037187
- Testing
- Blood Draw
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- University of Nebraska
Atopic Dermatitis, Psoriasis
Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases
Chronic inflammatory skin diseases constitute a heterogeneous group of pathologies. They affect the skin but also other organs (joints, lungs, muscles, etc.). Their prognosis and response to treatments is extremely variable.
- Conditions
- Atopic Dermatitis, Psoriasis, Hidradenitis Suppurativa, Lichen Planus
- Trial name
- ImmuneSkinBank (NCT06599411)
- Testing
- Sampling
- Where
- France
- Volunteers
- 830 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Bullous Pemphigoid
Treatment of Bullous Pemphigoid With Avdoralimab (IPH5401), an Anti-C5aR1 Monoclonal Antibody
The development of Auto Immune bullous Diseases (AIBD) results from a complex interaction between innate and adaptive immune systems.
- Trial name
- IPH (NCT04563923)
- Testing
- Avdoralimab (IPH5401), Control
- Where
- 4 sites in France
- Volunteers
- 15 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Pemphigus
Immunoadsorption, Dexamethasone Pulse Therapy and Rituximab for Pemphigus
Pemphigus is a severe autoimmune blistering disease mediated by circulating antibodies against certain proteins important for maintaining skin integrity.
- Trial name
- NCT00656656
- Testing
- Combination of Protein A Immunoadsorption, Rituximab, Dexamethasone plus Azathioprine
- Where
- Germany
- Volunteers
- 23 people
- Sponsor
- University of Luebeck
Autoimmune Bullous Disease
A Prospective & Retrospective Study on Ectopic Lymphoid-like Structures in Chronic Skins of Autoimmune Bullous Diseases
The purpose of this study is to identify the presence or absence of ectopic lymph node-like structures in skin lesions of patients with autoimmune bullous disease and the subtypes of the cells deposited there.
- Trial name
- NCT04509570
- Testing
- Biopsy
- Where
- South Korea
- Volunteers
- 41 people
- Sponsor
- Gangnam Severance Hospital
Ocular Cicatricial Pemphigoid
Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid
Cicatricial pemphigoid is an autoimmune blistering disease which affects the skin, mucous membranes, and, in a small subset of patients, the eye. Progressive ocular disease can lead to irreversible damage and blindness.
- Trial name
- NCT00584935
- Testing
- Rituximab
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Alabama at Birmingham
Bullous Pemphigoid
Validation of a Simplified Severity Score (Investigator Global Assessment: IGA) in Bullous Pemphigoid
The aim of the study is to validate a global and simple score : IGA (Investigator Global Assessment) score for the evaluation of the extent and severity of the disease in patients with bullous pemphigoid
- Trial name
- IGA score (NCT05366127)
- Testing
- IGA score, BULLOUS PEMPHIGOID DISEASE AREA INDEX (BPDAI)
- Where
- 11 sites in France
- Volunteers
- 150 people
- Sponsor
- University Hospital, Rouen
Bullous Pemphigoid (BP), Cold Agglutinin Disease (CAD)
Safety, Tolerability and Activity of BIVV009 in Healthy Volunteers and Patients With Complement Mediated Disorders
Prospective, double-blind, randomized, placebo-controlled First-In-Human study with four sub-parts: Part A, a single ascending dose study (SAD) in normal human volunteers (NHVs), Part B, a multiple ascending dose study (MAD) in…
- Conditions
- Bullous Pemphigoid (BP), Cold Agglutinin Disease (CAD), Warm Autoimmune Hemolytic Anemia (WAIHA), End-stage Renal Disease (ESRD)
- Trial name
- BIVV009-01 (NCT02502903)
- Testing
- BIV009
- Where
- Austria
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- Bioverativ, a Sanofi company
Bullous Keratopathy, Corneal Erosion
AONDA Therapeutic Indication Study I
This study will be used to support assessment of AIR OPTIX® NIGHT \& DAY® AQUA (AONDA) Soft Contact Lenses' safety and performance in accordance with updated European Union Medical Device Regulation (EU MDR) requirements.
- Conditions
- Bullous Keratopathy, Corneal Erosion, Entropion, Corneal Edema
- Trial name
- NCT05891106
- Testing
- Lotrafilcon A contact lenses
- Where
- 3 sites in United States
- Volunteers
- 55 people
- Sponsor
- Alcon Research
Pemphigoid, Bullous
The Effects of Tildrakizumab in Treatment of Bullous Pemphigoid
This is an open-label, pilot study evaluating the efficacy of tildrakizumab on the treatment of bullous pemphigoid (BP) in eligible patients (see detailed study protocol).
- Trial name
- NCT04465292
- Testing
- Tildrakizumab Prefilled Syringe
- Volunteers
- 16 people
- Sponsor
- Brigham and Women's Hospital